Related Experiment Video
Updated: Aug 5, 2026

The WinCF Model - An Inexpensive and Tractable Microcosm of a Mucus Plugged Bronchiole to Study the Microbiology of Lung Infections
Published on: May 8, 2017
Forced vital capacity in pulmonary exacerbations of cystic fibrosis
Oliver J McElvaney1, Sonya L Heltshe2, Don B Sanders3
1Cystic Fibrosis Therapeutics Development Network Coordinating Center, Seattle Children's Research Institute, Seattle, WA, USA; Division of Pulmonary, Critical Care and Sleep Medicine, University of Washington, Seattle, WA, USA.
Background:
Forced expiratory volume in one second (FEV₁) is routinely used to assess pulmonary exacerbations (PEx) in cystic fibrosis (CF) but underrepresents air trapping and small airways dysfunction. Forced vital capacity (FVC) may better capture these processes, yet its behavior, clinical relevance, and utility as a trial endpoint remain uncertain.
Methods:
We performed a secondary analysis of STOP2, a multicenter randomized trial of antimicrobial duration in adults with CF pulmonary exacerbations (PEx). Changes in percent-predicted FVC (ppFVC) and FEV₁ (ppFEV₁) were assessed relative to pre-PEx baseline. Clinical characteristics associated with large ppFVC decline were evaluated using adjusted analyses. Propensity score matching was used to compare recovery, residual deficit, and symptom response between groups with large versus modest ppFVC decline. Associations with time-to-next-exacerbation (TTNE) were assessed using survival analyses. Variability, responsiveness, and projected clinical trial sample sizes were compared between ppFVC- and ppFEV₁-based endpoints.
Results:
Among 760 participants, ppFVC responses were heterogeneous. Larger absolute declines were associated with higher baseline FVC and elevated C-reactive protein (CRP), while larger relative declines were associated with CRP alone. Participants with large initial ppFVC deficits showed greater absolute recovery but larger residual deficits, shorter TTNE, and higher future exacerbation risk. A one-standard-deviation worse residual ppFEV₁ deficit was associated with increased re-exacerbation risk, whereas residual ppFVC deficit was weaker and not independently prognostic. Absolute recovery in either measure was not associated with TTNE. Compared with ppFEV₁, ppFVC demonstrated similar or greater variability, resulting in larger estimated sample sizes for clinical trials.
Conclusions:
Distinct FVC response patterns occur during CF PEx but do not provide independent prognostic information beyond FEV₁. Use of ppFVC as a primary endpoint would require larger sample sizes without clear advantage.
More Related Videos
08:44Dual Test Gas Pulmonary Diffusing Capacity Measurement During Exercise in Humans Using the Single-Breath Method
Published on: February 2, 2024
05:56Implementation of Non-invasive Point of Care Transient Elastography for Evaluation of Liver Disease in Pediatric Populations with Cystic Fibrosis
Published on: August 29, 2025
Related Concept Videos
Cystic Fibrosis: Management
Sinus disease and chronic sinusitis...
Respiratory Capacities
One key metric is the Inspiratory Capacity (IC), which represents the maximum amount of air that can be inhaled with full effort. IC is calculated by summing the tidal volume and inspiratory reserve volume, typically ranging from 2.4 to 3.6 liters.
The Functional Residual Capacity (FRC) represents the air in the...
Chronic Obstructive Pulmonary Disease-IV: Assessement and Diagnostic Studies
Medical History
Pulmonary Function Tests
Pulmonary Function Tests are crucial diagnostic tools for assessing respiratory function, particularly in patients with chronic respiratory disorders. They comprehensively evaluate lung volumes, ventilatory function, breathing mechanics, diffusion, and gas exchange. These tests help diagnose pulmonary diseases and play a significant role in monitoring disease progression, evaluating disability, and assessing response to therapy.
PFTs involve using a spirometer, a...
Lung Capacity
Cystic Fibrosis: Pathogenesis
CF is primarily caused by a genetic mutation in a chromosome 7 gene coding for the cystic fibrosis transmembrane conductance regulator (CFTR) protein. The most common gene mutation leading to CF is the ΔF508 mutation, but...